New Hope: How Vaccines and Antibiotics Are Being Deployed Against Cancer in the UK

**Lead**

A quiet revolution is taking place in British oncology. Researchers across the United Kingdom are increasingly turning to two unlikely weapons in the fight against cancer: vaccines and antibiotics. While traditionally associated with preventing infectious diseases or treating bacterial infections, these medical tools are now being repurposed and re-engineered to target malignant cells. The implications for patient safety, treatment efficacy, and long-term survival are profound, particularly for cancers that have proven resistant to conventional therapies.

**Context**

The concept of using the body’s own immune system to fight cancer is not new. For decades, scientists have explored immunotherapies, but the specific deployment of vaccines designed to train the immune system to recognise and attack tumour cells has gained significant momentum in the past few years. In the UK, institutions such as the University of Oxford, the Institute of Cancer Research in London, and Cancer Research UK have been at the forefront of these efforts.

Cancer vaccines differ from traditional vaccines. Rather than preventing disease, they are therapeutic — given to patients who already have cancer. These personalised vaccines are often tailored to the genetic mutations present in an individual’s tumour. The process involves sequencing the tumour DNA, identifying neoantigens (unique markers on cancer cells), and creating a vaccine that prompts the immune system to target those markers. Early trials in the UK have shown promise in melanoma, lung cancer, and certain forms of pancreatic cancer.

Simultaneously, antibiotics are being studied for their off-target anti-cancer effects. Some antibiotics, such as doxycycline and azithromycin, have demonstrated the ability to inhibit mitochondrial function in cancer cells, effectively starving them of energy. Others, like metformin (used primarily for diabetes), have been shown to reduce cancer risk in patients. The NHS has supported several observational studies looking at whether common antibiotics can improve outcomes when combined with standard treatments. The potential safety advantage is significant: antibiotics are generally well-tolerated, inexpensive, and widely available, making them accessible across the healthcare system.

**Analise**

The shift towards vaccines and antibiotics represents a paradigm change in oncological safety. Traditional treatments such as chemotherapy and radiotherapy, while effective, come with harsh side effects — damage to healthy tissue, immunosuppression, and long-term toxicity. Vaccines offer a more targeted approach. Because they direct the immune system specifically to cancer cells, healthy cells are largely spared. This could reduce the burden on patients and on the NHS, which spends substantial resources managing treatment side effects.

Moreover, the security aspect extends beyond individual patient outcomes. The UK faces rising cancer incidence rates driven by an ageing population. Finding treatments that are both effective and cost-efficient is a matter of national health security. Antibiotics, many of which are off-patent and cheap, could be repurposed quickly and integrated into existing treatment protocols without the lengthy and expensive development pipelines required for new drugs. However, experts caution against over-optimism. Not all cancers respond to these approaches, and resistance remains a challenge, particularly with antibiotics. The risk of antibiotic resistance in bacteria must also be weighed carefully.

**Analise**

The UK’s integrated healthcare system provides a unique advantage for studying these therapies. Through the NHS, large-scale, real-world data can be collected, allowing researchers to observe outcomes across diverse populations. The National Cancer Research Institute has flagged vaccine development as a priority, and several phase 2 and phase 3 trials are underway. Meanwhile, the Medicines and Healthcare products Regulatory Agency (MHRA) has streamlined approval pathways for innovative therapies, including cancer vaccines.

For patients, the prospect of a treatment that does not cause hair loss, severe nausea, or increased infection risk is transformative. Clinicians report that vaccine therapies are often administered as an outpatient procedure, requiring only a series of injections. This improves quality of life and reduces hospital stays. In the context of the COVID-19 pandemic, which accelerated mRNA vaccine technology, scientists have been able to adapt that platform to cancer. BioNTech and Moderna, both of which have collaborated with UK research centres, are now conducting trials that leverage the same mRNA approach to target tumours.

**Fontes**

This article is based on publicly available information from Cancer Research UK, the National Health Service (NHS) England, the Institute of Cancer Research London, the University of Oxford’s Department of Oncology, the Medicines and Healthcare products Regulatory Agency, and peer-reviewed studies published in journals such as The Lancet Oncology and Nature Medicine. No specific individuals were named in compliance with editorial policy to avoid unverified claims.